HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

Hemoshear Therapeutics Logo
Published on : Published by : BioBuzz Media

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda. The milestone acknowledges development of a human tissue-based model of an undisclosed rare liver disease using the company’s REVEAL-Tx™ platform. REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context. 

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Published on : Published by : BioBuzz Media

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced that the first two patients have been dosed in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to advance the first oral therapy designed to directly address underlying biochemical causes of these rare and life-threatening diseases.

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Published on : Published by : BioBuzz Media

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019. Leveraging its proprietary REVEAL-TxTM disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon’s early discovery pipeline.